Corporate Overview


Our lead product: EGRIFTA®
Our lead product, EGRIFTA® (tesamorelin for injection), is the only treatment approved by the U.S. Food and Drug Administration indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

U.S. patients and healthcare professionals should refer to the website below for more information.